Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2012 (2012), Article ID 783739, 8 pages
Review Article

PET/CT in the Staging of the Non-Small-Cell Lung Cancer

Fangfang Chao1,2,3,4 and Hong Zhang1,2,3,4

1Department of Nuclear Medicine, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China
2Zhejiang University Medical PET Center, Zhejiang University, Hangzhou 310009, China
3Institute of Nuclear Medicine and Molecular Imaging, Zhejiang University, Hangzhou 310009, China
4Key Laboratory of Medical Molecular Imaging of Zhejiang Province, Hangzhou 310009, China

Received 1 January 2012; Accepted 20 January 2012

Academic Editor: Mei Tian

Copyright © 2012 Fangfang Chao and Hong Zhang. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Lung cancer is a common disease and the leading cause of cancer-related death in many countries. Precise staging of patients with non-small-cell lung cancer plays an important role in determining treatment strategy and prognosis. Positron emission tomography/computed tomography (PET/CT), combining anatomic information of CT and metabolic information of PET, is emerging as a potential diagnosis and staging test in patients with non-small-cell lung cancer (NSCLC). The purpose of this paper is to discuss the value of integrated PET/CT in the staging of the non-small-cell lung cancer and its health economics.